NCT00908349

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 214 (actual)
• Sponsor: Supernus Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 66 Years
• Healthy volunteers: Not accepted

Summary

Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)

Detailed description

NAP

Conditions

• Partial Epilepsy

Interventions

Type	Name	Description
DRUG	Oxcarbazepine XR	Open Label Study

Timeline

• Start date: 2009-06-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2009-05-25
• Last updated: 2017-05-31
• Results posted: 2017-05-31

Locations

58 sites across 8 countries: United States, Bulgaria, Canada, Croatia, Mexico, Poland, Romania, Russia